These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
132 related items for PubMed ID: 26980005
1. Agreement between ACT and aPTT during extracorporeal membrane oxygenation shows intra- and inter-individual variation. Cunningham D, Besser MW, Giraud K, Gerrard C, Vuylsteke A. Perfusion; 2016 Sep; 31(6):503-7. PubMed ID: 26980005 [Abstract] [Full Text] [Related]
6. An ex vivo comparison of partial thromboplastin time and activated clotting time for heparin anticoagulation in an ovine model. Berk ZBK, Shah A, Sun W, Griffith BP, Wu ZJ. Artif Organs; 2022 Mar; 46(3):501-505. PubMed ID: 34698388 [Abstract] [Full Text] [Related]
9. Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time. Ahn HY, Jung Y, Kim TW, Cho YH, Yang JH, Chung CR, Min MS, Ko RE. Ann Pharmacother; 2024 Apr; 58(4):383-390. PubMed ID: 37401103 [Abstract] [Full Text] [Related]
12. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, Rodriquez D, Weinstein S. Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992 [Abstract] [Full Text] [Related]
13. Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation. Buckley MS, Benanti GE, Meckel J, Tekle LA, Gilbert B, Puebla Neira D, McNierney DA, Korkames G, Yerondopoulos M, Park A, O'Hea JA, MacLaren R. Pharmacotherapy; 2023 Mar; 43(3):196-204. PubMed ID: 36759323 [Abstract] [Full Text] [Related]
16. Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation. Sulkowski JP, Preston TJ, Cooper JN, Duffy VL, Deans KJ, Chicoine LG, Minneci PC. J Extra Corpor Technol; 2014 Mar; 46(1):69-76. PubMed ID: 24779122 [Abstract] [Full Text] [Related]
17. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). Zavadil DP, Stammers AH, Willett LD, Deptula JJ, Christensen KA, Sydzyik RT. J Extra Corpor Technol; 1998 Jun; 30(2):83-90. PubMed ID: 10182118 [Abstract] [Full Text] [Related]
18. Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation. Hohlfelder B, Kelly D, Hoang M, Anger KE, Sylvester KW, Kaufman RM, Connors JM. Am J Ther; 2022 Jul 01; 29(4):e385-e393. PubMed ID: 31833874 [Abstract] [Full Text] [Related]
19. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Am J Clin Pathol; 2010 Dec 01; 134(6):950-4. PubMed ID: 21088159 [Abstract] [Full Text] [Related]
20. Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients. Mazzeffi MA, Tanaka K, Roberts A, Rector R, Menaker J, Kon Z, Deatrick KB, Kaczorowski D, Griffith B, Herr D. J Cardiothorac Vasc Anesth; 2019 May 01; 33(5):1216-1220. PubMed ID: 30181084 [Abstract] [Full Text] [Related] Page: [Next] [New Search]